Apellis Pharmaceuticals, Inc. - Common Stock (APLS)
22.10
-7.95 (-26.46%)
NASDAQ · Last Trade: Oct 30th, 2:46 PM EDT
Detailed Quote
Previous Close
30.05
Open
24.85
Bid
22.09
Ask
22.12
Day's Range
22.00 - 25.35
52 Week Range
16.10 - 35.72
Volume
5,927,011
Market Cap
2.57B
PE Ratio (TTM)
-12.14
EPS (TTM)
-1.8
Dividend & Yield
N/A (N/A)
1 Month Average Volume
2,431,005
Chart
About Apellis Pharmaceuticals, Inc. - Common Stock (APLS)
Apellis Pharmaceuticals is a biopharmaceutical company focused on developing innovative therapies for the treatment of serious diseases through its expertise in complement biology. The company works on advancing its proprietary drug candidates designed to modulate the immune system, with particular attention to rare and complex conditions that currently have limited treatment options. By harnessing advanced science and technology, Apellis aims to improve patient outcomes and address unmet medical needs in various therapeutic areas, including hematology and ophthalmology. Read More
Stay up-to-date with the latest market trends in the middle of the day on Thursday. Explore the top gainers and losers during today's session in our detailed report.
Apellis Pharmaceuticals (APLS) Q3 2025 earnings crushed estimates, driven by strong drug sales and a major partnership payment. The company achieved profitability and positive market reaction.
WALTHAM, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), today announced its third quarter 2025 financial results and business highlights.
WALTHAM, Mass., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced new data from the open-label period of the Phase 3 VALIANT study that reinforce the robust and sustained efficacy of EMPAVELI® (pegcetacoplan), a C3 inhibitor, in patients with C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN), rare and debilitating kidney diseases.
Apellis Pharmaceuticals to Host Conference Call on October 30, 2025, to Discuss Third Quarter 2025 F, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will host a conference call and webcast to discuss its third quarter 2025 financial results on Thursday, October 30, 2025, at 8:30 a.m. ET.
During the last three months, 12 analysts shared their evaluations of Apellis Pharmaceuticals (NASDAQ: APLS), revealing diverse outlooks from bullish to bearish. The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
Shares of Top KingWin Ltd (NASDAQ: WAI) rose sharply in pre-market trading after the company announced it entered into a sales contract with Walker Times International for the sale of 10,000 units of TK-D2C AI Robots.
WALTHAM, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that management will participate in webcast fireside chats at the following investor conferences:
Apellis Pharmaceuticals (APLS) reported mixed Q2 2025 results, missing revenue estimates ($178.49M vs. $192.29M) but beating EPS (-$0.33 vs. -$0.49). Shares rose 4.58% pre-market as FDA approval for EMPAVELI® boosts future prospects.
WALTHAM, Mass., July 31, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), today announced its second quarter 2025 financial results and business highlights.
WALTHAM, Mass., July 24, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will host a conference call and webcast to discuss its second quarter 2025 financial results on Thursday, July 31, 2025, at 8:30 a.m. ET.
